Supplementary Table S2 from Phase I trial of ganitumab plus dasatinib to cotarget the insulin-like growth factor 1 receptor and Src family kinase YES in rhabdomyosarcoma
Year: 2024
Type: supplementary-materials
Abstract: Adverse events possibly, probably, or definitely related to ganitumab across all 28 cycles (maximum grade per patient)
Authors: Srivandana Akshintala, R. Taylor. Sundby, Donna Bernstein, John W. Glod, Rosandra N. Kaplan, Marielle E. Yohe, Andrea M. Gross, Joanne Derdak, Haiyan Lei, Alexander Pan, Eva Dombi, Isabel Palacio-Yance, Kailey R. Herrera, Markku M. Miettinen, Helen X. Chen, Seth M. Steinberg, Lee J. Helman, Leo Mascarenhas, Brigitte C. Widemann, Fariba Navid, Jack F. Shern, Christine M. Heske
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402789499